newsfilter
← Earnings
Earnings Releases·

Edgewise Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported net income of $1,166.2 million ($10.71 basic, $9.65 diluted per share) for Q3 2026, a significant turnaround from a net loss of $40.7 million in Q3 2025, driven primarily by a $1,348 million gain on the sale of the sevasemten program.
  • Completed the sale of the sevasemten program and muscular dystrophy business to Servier in July 2026 for $1,396 million in upfront cash proceeds, increasing cash, cash equivalents, and marketable securities to $1,743.9 million as of September 30, 2026.
  • Initiated the Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) by the end of 2026, following positive Phase 2 Part D CIRRUS-HCM results and a published preclinical pharmacologic profile.
  • Dosed the first patient in the Phase 2 EQUINOX-HFpEF trial for EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction, while R&D expenses decreased to $31.6 million in Q3 2026 from $37.5 million in the prior year period.
Company
EDGEWISE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology